Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
4502 On Other Exchanges
Symbol
Exchange
4502 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutical co ltd (4502) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TAKEDA PHARMACEUTICAL CO LTD (4502)

Related News

No related news articles were found.

takeda pharmaceutical co ltd (4502) Details

Takeda Pharmaceutical Company Limited engages in the research and development, manufacture, marketing, and sale of pharmaceutical products worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, central nervous system, immunology and respiratory, general medicine, oncology, gastroenterology, and vaccines. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

31,328 Employees
Last Reported Date: 06/26/15
Founded in 1781

takeda pharmaceutical co ltd (4502) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥230.0M
Senior Managing Director, Senior Vice Preside...
Total Annual Compensation: ¥85.0M
Compensation as of Fiscal Year 2015.

takeda pharmaceutical co ltd (4502) Key Developments

H. Lundbeck A/S and Takeda Pharmaceutical Company Limited Announce FDA Accepts a Supplemental New Drug Application for Review of Brintellix (Vortioxetine) Clinical Trial Data

H. Lundbeck A/S and Takeda Pharmaceutical Company Limited announced the US Food and Drug Administration has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive dysfunction in adults with Major Depressive Disorder (MDD) to the current product label. Brintellix is currently approved and available in the US for the treatment of MDD in adults. The FDA is expected to take action on this filing by 28 March 2016. Depression includes a range of symptoms including cognitive ones. The cognitive symptoms of depression may go unrecognized by both healthcare providers and patients. Common cognitive complaints include difficulty concentrating, indecisiveness, trouble thinking and forgetfulness. These symptoms are common and many of them often persist between major depressive episodes. According to a three-year prospective study of people treated for depression, cognitive symptoms (defined as diminished ability to think or concentrate and/or indecisiveness) were reported 94% of the time during major depressive episodes and 44% of the time between major depressive episodes (or during periods of partial remission). The sNDA is primarily based on the FOCUS and CONNECT studies, which were specifically designed to assess the effect of Brintellix on certain aspects of cognitive function in adult patients with MDD utilizing objective measures of cognitive function. These two 8-week, randomized, double-blind, placebo-controlled studies of Brintellix 10 and 20 mg/day used a well-established neuropsychological test (the Digit Symbol Substitution Test or DSST). The DSST performance measurement involves executive function, processing speed and attention. The FDA approved Brintellix on 30 September 2013 for the treatment of MDD in adults. Brintellix is furthermore approved in 55 countries (including Europe, Canada, Chile, Mexico, Argentina, South Korea, Turkey, Australia, Hong Kong, Singapore and South Africa). It is available in approximately 30 countries to date.

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Second Quarter and Full Year 2015

Takeda Pharmaceutical Company Limited provided dividend guidance for the second quarter and full year 2015. For the second quarter of 2015, the company expects to pay a dividend of JPY 90.00 per share. For the year 2015, the company expects to pay a dividend of JPY 90.00 per share.

Takeda Pharmaceutical Company Limited Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to EMA, FDA and PMDA

Takeda Pharmaceutical Company Limited announced the completion of the study to fulfill the post-marketing commitment and submissions of data to regulatory authorities from the Pan European Multi-Database Bladder Cancer Risk Characterization Study, (n= 112,674), multi-database retrospective matched cohort study, conducted in four European countries, for pioglitazone containing medicines, including ACTOS (pioglitazone HCI) with up to 10 years of follow-up. Findings demonstrate that there is no association between the use of pioglitazone and the risk of bladder cancer, (hazard ratio [HR] 0.99 [95% CI: 0.75, 1.30]). These results are consistent with those of a 10-year, prospective cohort study, conducted by the University of Pennsylvania (U. of Penn.) and Division of Research at Kaiser Permanente Northern California (KPNC), which demonstrated no increased risk of bladder cancer among patients ever exposed to pioglitazone ([HR] 1.06 [95% CI 0.89-1.26]). Additionally, both studies found no association between the risk of bladder cancer and cumulative dose of pioglitazone, or duration of pioglitazone exposure. The data from the Pan European Multi-Database Bladder Cancer Risk Characterization Study also shows a mortality decrease with ever use of pioglitazone (adjusted HR 0.67 [95% CI: 0.64, 0.70]). This study was completed as part of the post-marketing request from the Committee for Medicinal Products for Human Use (CHMP). In addition to the European Medicines Agency (EMA), the results from the Pan European study were also submitted to the U.S. Food and Drug Administration (FDA) and the Japanese Ministry of Health, Labour and Welfare (MHLW)/Pharmaceuticals and Medical Devices Agency (PMDA).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4502:JP ¥5,670.00 JPY -82.00

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $43.07 USD -1.07
Baxter International Inc $36.14 USD -0.91
Becton Dickinson and Co $134.32 USD -2.21
Biogen Inc $302.26 USD +0.63
Merck KGaA €83.48 EUR -1.84
View Industry Companies
 

Industry Analysis

4502

Industry Average

Valuation 4502 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.5x
Price/Book 2.1x
Price/Cash Flow 189.8x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit www.takeda.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.